Keywords: Human Genome Sciences, Zalbin, Jouleferon, Hepatitis C, Novartis

Human Genome Sciences sees little hope of FDA approval for hep C drug Zalbin in bi-monthly regimen

Article | 15 June 2010

Based on preliminary written feedback from the US Food and Drug Administration regarding Human Genome Sciences’ Biologics License Application seeking ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Human Genome Sciences

Go to company listing

Related Drugs

Zalbin

Jouleferon

Go to drug listing